Clover Biopharmaceuticals Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	51.77	38.42	39.26	-	-	-
Revenue Growth (YoY)	79.16%	-2.13%	-	-	-	-
Cost of Revenue	711.17	711.36	1,712	475.64	66.27	-
Gross Profit	-659.39	-672.94	-1,673	-475.64	-66.27	-
Selling, General & Admin	80.22	94.88	253.58	410.24	345.71	76.43
Research & Development	168.34	183.39	649.89	1,465	1,826	228.22
Other Operating Expenses	3.53	3.63	24.59	49.01	0.43	31.96
Operating Expenses	252.09	281.9	928.05	1,925	2,172	336.61
Operating Income	-911.48	-954.84	-2,601	-2,400	-2,239	-336.61
Interest Expense	-1.66	-5.76	-18.72	-5.93	-8.22	-2.97
Interest & Investment Income	15.06	23.69	16.12	8.51	10.89	3.41
Currency Exchange Gain (Loss)	-24.54	-23.85	-34.98	-25.41	10.35	-
Other Non Operating Income (Expenses)	11.59	16.58	12.43	14.51	16.11	20.93
EBT Excluding Unusual Items	-911.04	-944.19	-2,626	-2,409	-2,210	-315.24
Merger & Restructuring Charges	-3.41	-	-	-13.84	-	-
Gain (Loss) on Sale of Investments	0.58	0.4	-	0.23	0.91	-
Gain (Loss) on Sale of Assets	-0.11	2	-4.74	-8.43	-	-
Asset Writedown	-14.01	-14.01	-10.31	-	-	-
Other Unusual Items	18.42	52.37	2,503	-21.32	-3,808	-597.66
Pretax Income	-909.58	-903.43	-138.54	-2,452	-6,016	-912.9
Net Income	-909.58	-903.43	-138.54	-2,452	-6,016	-912.9
Net Income to Common	-909.58	-903.43	-138.54	-2,452	-6,016	-912.9
Shares Outstanding (Basic)	1,257	1,254	1,244	1,102	1,158	758
Shares Outstanding (Diluted)	1,257	1,254	1,244	1,102	1,158	758
Shares Change (YoY)	0.63%	0.82%	12.83%	-4.84%	52.85%	-
EPS (Basic)	-0.72	-0.72	-0.11	-2.22	-5.19	-1.20
EPS (Diluted)	-0.72	-0.72	-0.11	-2.22	-5.19	-1.20
Free Cash Flow	-246.53	-289.62	-734.83	-1,768	-977	363.31
Free Cash Flow Per Share	-0.20	-0.23	-0.59	-1.60	-0.84	0.48
Operating Margin	-1760.53%	-2485.33%	-6626.46%	-	-	-
Profit Margin	-1756.85%	-2351.51%	-352.92%	-	-	-
Free Cash Flow Margin	-476.18%	-753.84%	-1871.94%	-	-	-
EBITDA	-888.18	-926.43	-2,563	-2,371	-2,226	-335.04
D&A For EBITDA	23.3	28.41	38.3	28.98	12.29	1.57
EBIT	-911.48	-954.84	-2,601	-2,400	-2,239	-336.61

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.